Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Hookipa Pharma develops proprietary arenavirus-based immunotherapies targeting cancers and infectious diseases. Its platform induces robust, durable T cell and antibody responses, leveraging both replicating and non-replicating technologies. Core programs include cancer treatments for KRAS-mutated tumors, HPV-related cancers, and self-antigen prostate cancer, as well as infectious disease vaccines for hepatitis B and HIV, often in partnership with Gilead. The company focuses on immuno-oncology and infectious disease applications with a modular, immune system-reprogramming approach.
This description was generated via AI from an annual report. Updated about 1 year ago.